Board of Directors
Peter Allen
Chairman & Acting Chief Executive
Peter Allen ACA was appointed Acting Chief Executive in September 2010, having been Non-Executive Chairman since December 2007. He was CFO and Deputy CEO of Celltech Group plc between 1992 and 2004. In addition to managing the company's flotation process in 1993, leading to a listing on the London Stock Exchange, Peter played a key role in several strategic acquisitions, including Chiroscience, Medeva and Oxford Glycosciences. In May 2004, Peter was a key participant in the sale of Celltech to UCB. Prior to this, he was Group Financial Controller of Associated British Ports Holdings plc and Financial Controller with L'Oreal (UK) Ltd. In April 2005, he was appointed CFO of Abacus Group plc, the quoted electronics distributor. Peter Allen is chairman of the Nomination Committee and a member of the Remuneration Committee and the Audit Committee.
Peter Cawdron
Senior Independent Director
Peter Cawdron is a qualified chartered accountant and spent 14 years from 1983 as Group Strategy Director with Grand Metropolitan, becoming a director in 1993. Previously he spent six years in the US as Chief Financial Officer of a major advertising agency preceded by seven years in merchant banking at SG Warburg. He currently serves on the Board of a number of public companies including Capita Group plc, Compass Group plc, Punch Taverns plc and GCap Media plc. Peter Cawdron is chairman of the Audit Committee and a member of the Remuneration Committee and the Nomination Committee.
Dr Michael Asbury
Non-Executive
Dr Michael Asbury is medically qualified and obtained an MRCP(UK) in 1973. He has held numerous general management and marketing positions in the pharmaceutical industry. In particular, he was International Marketing Director with Zeneca Pharmaceuticals and Vice President of Global Licensing at AstraZeneca. He has wide international experience of the development and marketing of ethical pharmaceuticals and all forms of corporate activity in the pharmaceutical industry. In addition, he is the non-executive chairman of Photopharmica, a non-executive board member of IPR Pharmaceuticals Puerto Rico and a trustee board member of the David Lewis National Epilepsy Centre. Dr Michael Asbury is chairman of the Remuneration Committee and a member of the Audit Committee.
Dr Frank Fildes
Non-Executive
Dr Frank Fildes was, until 2002, Senior Vice President, Head of Global Development with AstraZeneca where he had responsibility for the development, registration and support of the Company's worldwide product range. A physical chemist by training, he started his pharmaceutical career with ICI Pharmaceuticals and carried out a range of senior management roles with ICI and its successor, Zeneca Pharmaceuticals, including Head of Global Development Projects and Senior Vice President PreClinical Sciences. Dr Frank Fildes is a Fellow of the Royal Society of Medicine and the Royal Society of Chemistry. Dr Frank Fildes is a member of the Nomination Committee.
Simon Turton
Non-Executive
Dr. Simon Turton is a Managing Director in the Healthcare group at Warburg Pincus, the global private equity firm. Before joining Warburg Pincus in 2002, he was a Principal at Index Ventures in Geneva. Previously, Simon worked for Servier, the French pharmaceutical company, where he managed Northern Asia operations in Tokyo and Paris. He also worked for a pharmaceutical strategic alliances consultancy where he was in charge of business development. Dr. Turton has an M.B.A. from INSEAD, which he attended as a Sainsbury Management Fellow in the Life Sciences, and a Ph.D. in Pharmacy from the University of London. He is a director of Archimedes Pharma, ProStrakan and Tornier.
Allan Watson
Chief Financial Officer
Allan Watson joined ProStrakan as Chief Financial Officer (CFO) in September 2009. Allan joined the Company from medical technology business, Optos plc, where he had been CFO since 2003. A pharmacy graduate, he has held a number of finance positions with companies both within and outside the healthcare sector since qualifying as an accountant.
